Table 3.
Adherence and Adverse Events of First-Line Helicobacter pylori Eradication Therapy
| Variable | Tegoprazan-based triple therapy (n=344) |
Rabeprazole-based triple therapy (n=333) |
p-value |
|---|---|---|---|
| Adherence* | 313 (91.0) | 297 (89.2) | 0.443 |
| Non-adjherence | 31 (9.0) | 36 (10.8) | |
| Loss of follow-up | 24 (7.0) | 34 (10.2) | |
| Insufficient medication | 7 (2.0) | 2 (0.6) | |
| Adverse event† | |||
| Any adverse event | 95 (27.6) | 86 (25.8) | 0.604 |
| General weakness | 1 (0.3) | 0 | >0.999 |
| Dizziness | 0 | 0 | NA |
| Headache | 3 (0.9) | 2 (0.6) | >0.999 |
| Myalgia | 0 | 0 | NA |
| Acid regurgitation | 0 | 0 (0.1) | 0.492 |
| Nausea or vomiting | 16 (4.7) | 14 (4.2) | 0.853 |
| Dysgeusia | 43 (12.5) | 33 (9.9) | 0.330 |
| Abdominal discomfort | 8 (2.3) | 10 (3.0) | 0.639 |
| Abdominal pain | 2 (0.6) | 1 (0.3) | >0.999 |
| Diarrhea | 27 (7.8) | 40 (12.0) | 0.073 |
| Constipation | 3 (0.9) | 0 | 0.249 |
| Skin rash | 5 (1.5) | 2 (0.6) | 0.451 |
| Others‡ | 4 (1.2) | 1 (0.3) | 0.373 |
| Confirmation test for H. pylori eradication | 0.003 | ||
| Urea breath test | 307 (96.2) | 302 (99.7) | |
| Histologic evaluation with modified Giemsa staining | 12 (3.8) | 1 (0.3) | |
| Lag period for confirmation test after eradication therapy | 0.016 | ||
| <2 wk | 1 (0.3) | 0 | |
| 2–4 wk | 10 (3.1) | 10 (3.3) | |
| 4–12 wk | 307 (96.2) | 283 (93.4) | |
| 12–24 wk | 1 (0.3) | 10 (3.3) | |
Data are presented as number (%).
NA, not applicable.
*Adherence is determined as administration of ≥80% of prescribed medications; †Percentage is calculated based on the intention-to-treat population; ‡Other adverse events include sores on the tongue, dry mouth, palpitation, anal bleeding, and insomnia.